Active Ingredient History
Glyburide, a second-generation sulfonylurea antidiabetic agent, lowers blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glibenclamide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide. Sulfonylureas such as glyburide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin. Glyburide is indicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone. Glyburide is available as a generic, is manufactured by many pharmaceutical companies and is sold in doses of 1.25, 2.5 and 5 mg under many brand names including Gliben-J, Daonil, Diabeta, Euglucon, Gilemal, Glidanil, Glybovin, Glynase, Maninil, Micronase and Semi-Daonil. It is also available in a fixed-dose combination drug with metformin that is sold under various trade names, e.g. Bagomet Plus, Benimet, Glibomet, Gluconorm, Glucored, Glucovance, Metglib and many others. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Albuminuria (Phase 4)
Angina Pectoris (Phase 1)
Blood Glucose (Phase 2)
Blood Pressure (Phase 4)
Brain Edema (Phase 3)
Brain Injuries, Traumatic (Phase 2)
Brain Neoplasms (Phase 1/Phase 2)
Cardiomegaly (Phase 4)
Carotid Artery Diseases (Phase 4)
Coronary Artery Disease (Phase 4)
Diabetes, Gestational (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Endothelial Cells (Phase 4)
Exercise (Phase 4)
Gestational Age (Phase 3)
Glucose Metabolism Disorders (Phase 2)
Healthy Volunteers (Phase 1)
Hypertension (Phase 4)
Hypoglycemic Agents (Phase 4)
Ischemic Stroke (Phase 2)
Liver (Phase 4)
Neoplasm Metastasis (Phase 2)
Obesity (Phase 4)
Pregnancy (Phase 3)
Pregnancy in Diabetics (Phase 4)
Spinal Cord Injuries (Phase 1/Phase 2)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 4)
Vascular Stiffness (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
